Android vs iOS
Listening to the Abbott presentation and corresponding Q&A a few things are becoming clearer in the expanding CGM market.
1. The company noted there are now over 1 million patients using the Libre with 200,000 domestically and 800,000 overseas. This has generated sales approaching $1 Billion.
2. There is no question that Abbott is committed to providing Libre at a lower price point than Dexcom, noting several times that Libre is an “affordable” CGM.
3. In an interesting twist the company made a point to mention that getting the Libre to work is . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.